Preview

Научно-практическая ревматология

Расширенный поиск

Можно ли предотвратить развитие псориатического артрита у пациентов с псориазом?

https://doi.org/10.14412/1995-4484-2019-250-254

Полный текст:

Аннотация

Псориатический артрит (ПсА) – хроническое иммуновоспалительное заболевание, которое, с одной стороны, рассматривается как наиболее частая коморбидная патология при псориазе в рамках «системной псориатической болезни», а с другой – классифицируется как клиническая форма спондилоартритов и находится на стыке фундаментальных проблем ревматологии и дерматологии. Изучение эволюции псориаза в направлении развития ПсА является приоритетным направлением исследований в ревматологии и дерматологии, имеющим важное значение для расшифровки природы гетерогенности и механизмов иммунопатогенеза этих заболеваний и разработки новых методов персонифицированной терапии на разных стадиях заболеваний.

Об авторах

Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия

115522, Москва, Каширское шоссе, 34А.

119991, Москва, ул. Трубецкая, 8, стр. 2.



Т. В. Коротаева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А.



А. М. Лила
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А.


А. А. Кубанов
ФГБНУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Россия

107076, Москва, ул. Короленко, 6, стр. 6.



Список литературы

1. Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol. 2006 Feb;33(2):210-2.

2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957-70. doi: 10.1056/NEJMra1505557

3. Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1-8. doi: 10.1016/j.coi.2017.07.007

4. Chimenti MS, Caso F, Alivernini S, et al. Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. Autoimmun Rev. 2019;18(6):565-75. doi: 10.1016/j.autrev.2018.11.007

5. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273-84. doi: 10.1016/S0140-6736(18)30830-4

6. Christophers E, van de Kerkhof PCM. Severity, heterogeneity and systemic inflammation in psoriasis. J Eur Acad Dermatol Venereol. 2019;33(4):643-7. doi: 10.1111/jdv.15339

7. Tillett W, Charlton R, Nightingale A, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatology (Oxford). 2017;56(12):2109-13. doi: 10.1093/rheumatology/kex323

8. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045-50. doi: 10.1136/annrheumdis-2013-204858

9. Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5(1):e000870. doi: 10.1136/rmdopen-2018-000870

10. Van Steenbergen HW, da Silva JAP, Huizinga TWJ, van der Helmvan Mil AHM. Preventing progression from arthralgia to arthritis: targeting the right patients. Nat Rev Rheumatol. 2018;14(1):32-41. doi: 10.1038/nrrheum.2017.185

11. Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153-66. doi: 10.1038/s41584-019-0175-0

12. Scher JU. The 2018 landscape of RA, PsA, and SpA pathogenesis. Curr Opin Rheumatol. 2018;30:57-8. doi: 10.1097/BOR.0000000000000461

13. Насонов ЕЛ. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86 [Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.)]. doi: 10.14412/1995-4484-2017-68-86

14. Kim HJ, Lebwohl MG. Biologics and Psoriasis: The Beat Goes On. Dermatol Clin. 2019;37(1):29-36. doi: 10.1016/j.det.2018.07.004

15. FitzGerald O, Ritchlin C. Opportunities and challenges in the treatment of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):440-52. doi: 10.1016/j.berh.2019.03.001

16. Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheum. 2019;71(1):5-32. doi: 10.1002/art.40726

17. Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018;391(10136):2285-94. doi: 10.1016/S0140-6736(18)30949-8

18. Okhovat JP, Ogdie A, Reddy SM, et al. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: benefits and challenges of combined rheumatology-dermatology clinics. J Rheumatol. 2017;44(5):693-4. doi: 10.3899/jrheum.170148

19. Siegel EL, Orbai AM, Ritchlin CT. Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. Curr Opin Rheumatol. 2015;27:111-7. doi: 10.1097/BOR.0000000000000155

20. Насонов ЕЛ. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-94 [Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.)]. doi: 10.14412/1995-4484-2017-277-294

21. Boeters DM, Raza K, van der Helm-van Mil AHM. Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art. RMD Open. 2017;3(2):e000479. doi: 10.1136/rmdopen-2017-000479. eCollection 2017.

22. Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol. 2014;10:212-28. doi: 10.1038/nrrheum.2014.6

23. Watad A, Bridgewood C, Russell T, et al. The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science. Front Immunol. 2018;9:2668. doi: 10.3389/fimmu.2018.02668

24. Olsen NJ, Karp DR. Autoantibodies and SLE: the threshold for disease. Nat Rev Rheumatol. 2014;10:181-6. doi: 10.1038/nrrheum.2013.184

25. Winthrop KL, Weinblatt ME, Crow MK, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Ann Rheum Dis. 2019 Feb 2. pii: annrheumdis-2018-214280. doi: 10.1136/annrheumdis-2018-214280

26. Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheum. 2016;68(4):915-23. doi: 10.1002/art.39494

27. Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225(3):231-5. doi: 10.1159/000343607

28. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017 Mar;76(3):377-90. doi: 10.1016/j.jaad.2016.07.064

29. Eder L, Polachek A, Rosen CF, et al. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheum. 2017;69(3):622-9. doi: 10.1002/art.39973. Erratum in: Arthritis Rheum. 2019;71(4):625. doi: 10.1002/art.40887

30. Thorarensen SM, Lu N, Ogdie A, et al. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2017;76:521-5. doi: 10.1136/annrheumdis-2016-209334

31. Van Mechelen M, Lories RJ. Microtrauma: no longer to be ignored in spondyloarthritis? Curr Opin Rheumatol. 2016;28:176-80. doi: 10.1097/BOR.0000000000000254

32. FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17:115. doi: 10.1186/s13075-015-0640-3

33. Stuart PE, Nair RP, Tsoi LC, et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015;97(6):816-36. doi: 10.1016/j.ajhg.2015.10.019

34. Aterido A, Canete JD, Tornero J, et al. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Ann Rheum Dis. 2019;78(3). pii: e214158. doi: 10.1136/annrheumdis-2018-214158. Epub 2018 Dec 14.

35. Feld J, Chandran V, Haroon N, et al. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018;14(6):363-71. doi: 10.1038/s41584-018-0006-8

36. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-90. doi: 10.1007/s12016-018-8702-3

37. Schön MP, Erpenbeck L. The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis. Front Immunol. 2018;9:1323. doi: 10.3389/fimmu.2018.01323

38. Mylle S, Grine L, Speeckaert R, et al. Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly. Am J Clin Dermatol. 2018;19(5):625-37. doi: 10.1007/s40257-018-0366-5

39. Mattozzi C, Salvi M, D’Epiro S, et al. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature. Dermatology. 2013;227(2):134-45. doi: 10.1159/000353398

40. Насонов ЕЛ, Александрова ЕН, Авдеева АС, Рубцов ЮП. Т-регуляторные клетки при ревматоидном артрите. Научно-практическая ревматология. 2014;52(4):430-7 [Nasonov EL, Aleksandrova EN, Avdeeva AS, Rubtsov YuP. T regulatory cells in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):430-7 (In Russ.)]. doi: 10.14412/1995-4484-2014-430-437

41. Авдеева АС, Рубцов ЮП, Дыйканов ДТ, Насонов ЕЛ. Клинико-патогенетическое значение Foxр3+ регуляторных Т-клеток при ревматоидном артрите. Научно-практическая ревматология. 2016;54(4):442-55 [Avdeeva AS, Rubtsov YuP, Dyikanov DT, Nasonov EL. The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):442-55 (In Russ.)]. doi: 10.14412/1995-4484-2016-442-455

42. Pereira LMS, Gomes STM, Ishak R, Vallinoto ACR. Regulatory T Cell and Forkhead Box Protein 3 as Modulators of Immune Homeostasis. Front Immunol. 2017;8:605. doi: 10.3389/fimmu.2017.00605

43. Scher JU, Littman DR, Abramson SB. Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheum. 2016;68:35-45. doi: 10.1002/art.39259

44. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis. 2013;72:1200-5. doi: 10.1136/annrheumdis-2012-202143

45. Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheum. 2015;67(1):128-39. doi: 10.1002/art.38892

46. Авдеева АС. ИФНγ-индуцируемый белок 10 (IP-10) при ревматоидном артрите: обзор литературы и собственные данные. Научно-практическая ревматология. 2017;55(6):655-61 [Avdeeva AS. IFN-γ-induced protein 10 (IP-10) in rheumatoid arthritis: literature review and the authors' own data. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):655-661 (In Russ.)]. doi: 10.14412/1995-4484-2017-655-661

47. Abji F, Pollock RA, Liang K, et al. Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheum. 2016;68:2911-6. doi: 10.1002/art.39800

48. Cretu D, Gao L, Liang K, et al. Differentiating psoriatic arthritis from psoriasis without psoriatic arthritis using novel serum biomarkers. Arthritis Care Res (Hoboken). 2018;70(3):454-61. doi: 10.1002/acr.23298

49. Cretu D, Liang K, Saraon P, et al. Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers. Clin Proteomics. 2015;12(1):1. doi: 10.1186/1559-0275-12-1

50. Frasca L, Palazzo R, Chimenti MS, et al. Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. Front Immunol. 2018;9:1936. doi: 10.3389/fimmu.2018.01936

51. Yuan Y, Qiu J, Lin ZT, et al. Identification of Novel Autoantibodies Associated With Psoriatic Arthritis. Arthritis Rheum. 2019;71(6):941-51. doi: 10.1002/art.40830

52. Gisondi P, Tinazzi I, El-Dalati G, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis. 2008;67:26-30. doi: 10.1136/ard.2007.075101

53. Simon D, Faustini F, Kleyer A, et al. Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis. 2016;75(4):660-6. doi: 10.1136/annrheumdis-2014-206347

54. Tinazzi I, McGonagle D, Biasi D, et al. Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis. J Rheumatol. 2011;38(12):2691-2. doi: 10.3899/jrheum.110505

55. Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4):632-7. doi: 10.1016/j.semarthrit.2018.05.011

56. Колтакова АД. Регистры псориатического артрита. Обзор литературы. Научно-практическая ревматология. 2019;57(2):210-7 [Koltakova AD. Registers of psoriatic arthritis. Literature review. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):210-7 (In Russ.)]. doi: 10.14412/1995-4484-2019-210-217


Для цитирования:


Насонов Е.Л., Коротаева Т.В., Лила А.М., Кубанов А.А. Можно ли предотвратить развитие псориатического артрита у пациентов с псориазом? Научно-практическая ревматология. 2019;57(3):250-254. https://doi.org/10.14412/1995-4484-2019-250-254

For citation:


Nasonov E.L., Korotaeva T.V., Lila A.M., Kubanov A.A. Can the development of psoriatic arthritis be prevented in patients with psoriasis? Rheumatology Science and Practice. 2019;57(3):250-254. (In Russ.) https://doi.org/10.14412/1995-4484-2019-250-254

Просмотров: 30


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)